Corticosteroid Burden and Hearing Outcomes in Eosinophilic Otitis Media with and without Biologic Therapy: A Pilot Retrospective Cohort Study.
- 1Department of Otolaryngology and Head and Neck Surgery, Yokohama City University Medical Center, Yokohama, Japan, [email protected].
- 2Department of Otolaryngology and Head and Neck Surgery, Yokohama City University School of Medicine, Yokohama, Japan.
- 3Department of Otolaryngology and Head and Neck Surgery, Yokohama City University Medical Center, Yokohama, Japan.
Abstract
Introduction
Eosinophilic otitis media (EOM) is a refractory, type 2-driven form of otitis media that often requires repeated local and/or systemic corticosteroid therapy. Biologic agents prescribed for comorbid type 2 airway disease may improve EOM outcomes; however, comparative real-world data remain limited. Therefore, we aimed to evaluate changes in EOM severity, air-conduction pure-tone average (PTA), and corticosteroid treatment burden in patients with EOM treated with and without biologic therapy in a single-center retrospective cohort.Methods
We retrospectively reviewed consecutive patients with EOM treated at a single tertiary center. The index date was defined as initiation of biologic therapy (dupilumab or mepolizumab) in the biologics group and initiation of EOM-directed corticosteroid therapy (systemic and/or intratympanic) in the non-biologics group. Post-index outcomes were assessed within a prespecified 10- to 14-month window, selecting the visit closest to 12 months. The primary analysis was conducted at the patient level, averaging bilateral ear outcomes when applicable. Primary outcomes were the EOM severity score (0-10) and air-conduction PTA (0.5/1/2/4 kHz).Results
Fourteen patients (24 ears) were included (mean age: 57.3 ± 9.3 years; three men/11 women)in this study, with 7 patients per group. Follow-up timing was standardized (median: 12.5 months; interquartile range [IQR]: 12.0-13.0). Baseline severity score and air-conduction PTA differed between groups (4.9 ± 1.7 vs. 5.7 ± 1.1; 39.6 ± 19.0 vs. 55.0 ± 19.0 dB, respectively). Severity improved in both groups; however, the between-group difference in change did not reach statistical significance (p = 0.077). Air-conduction PTA improved within the biologics group (p = 0.031); however, the between-group difference in PTA change was not significant (p = 0.249). Systemic corticosteroids were discontinued in the biologics group (0.00 ± 0.00 mg/day) but remained required in the non-biologics group (1.35 ± 1.55 mg/day; p = 0.011).Conclusion
In this pilot real-world cohort, biologic therapy used for comorbid type 2 airway disease was associated with a reduced corticosteroid burden and lower post-index EOM severity. Air-conduction PTA improved within the biologics group; however, the between-group difference in PTA change was not statistically significant, and the hearing findings should therefore be considered exploratory. These preliminary findings should be interpreted cautiously and may help inform adequately powered future studies.
Related
- Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?
- Eosinophilic Bronchiolitis Diagnosed by a Transbronchial Lung Cryobiopsy and Successfully Treated with Biologic Agents: A Report of Two Cases and Literature Review
- Comparative efficacy and safety of dupilumab and swallowed topical corticosteroid formulations in eosinophilic esophagitis : A systematic review and network meta-analysis of randomized controlled trials
- Ultrasound-Guided Versus Landmark-Guided Corticosteroid Injections for De Quervain’s Tenosynovitis: A Retrospective Comparative Study
- Predictors of Response to Corticosteroid Therapy in Idiopathic Granulomatous Mastitis: A Retrospective Cohort Study of 176 Patients
BibTeX
@article{wada2026corticosteroid,
title = {{Corticosteroid Burden and Hearing Outcomes in Eosinophilic Otitis Media with and without Biologic Therapy: A Pilot Retrospective Cohort Study.}},
author = {Takashi Wada and Yasuhiro Arai and Yoshihiro Aizawa and Kiyoshi Sakasai and Hiromitsu Hatakeyama and Nobuhiko Oridate},
journal = {ORL; journal for oto-rhino-laryngology and its related specialties},
year = {2026},
month = oct,
doi = {10.1159/orl/aegag008},
url = {https://europepmc.org/article/MED/42879375},
note = {CC BY},
}
RIS
TY - JOUR
TI - Corticosteroid Burden and Hearing Outcomes in Eosinophilic Otitis Media with and without Biologic Therapy: A Pilot Retrospective Cohort Study.
AU - Takashi Wada
AU - Yasuhiro Arai
AU - Yoshihiro Aizawa
AU - Kiyoshi Sakasai
AU - Hiromitsu Hatakeyama
AU - Nobuhiko Oridate
PY - 2026
DA - 2026/10/15
JO - ORL; journal for oto-rhino-laryngology and its related specialties
DO - 10.1159/orl/aegag008
UR - https://europepmc.org/article/MED/42879375
AB - Introduction Eosinophilic otitis media (EOM) is a refractory, type 2-driven form of otitis media that often requires repeated local and/or systemic corticosteroid therapy. Biologic agents prescribed for comorbid type 2 airway disease may improve EOM outcomes; however, comparative real-world data remain limited. Therefore, we aimed to evaluate changes in EOM severity, air-conduction pure-tone average (PTA), and corticosteroid treatment burden in patients with EOM treated with and without biologic therapy in a single-center retrospective cohort.Methods We retrospectively reviewed consecutive patients with EOM treated at a single tertiary center. The index date was defined as initiation of biologic therapy (dupilumab or mepolizumab) in the biologics group and initiation of EOM-directed corticosteroid therapy (systemic and/or intratympanic) in the non-biologics group. Post-index outcomes were assessed within a prespecified 10- to 14-month window, selecting the visit closest to 12 months. The primary analysis was conducted at the patient level, averaging bilateral ear outcomes when applicable. Primary outcomes were the EOM severity score (0-10) and air-conduction PTA (0.5/1/2/4 kHz).Results Fourteen patients (24 ears) were included (mean age: 57.3 ± 9.3 years; three men/11 women)in this study, with 7 patients per group. Follow-up timing was standardized (median: 12.5 months; interquartile range [IQR]: 12.0-13.0). Baseline severity score and air-conduction PTA differed between groups (4.9 ± 1.7 vs. 5.7 ± 1.1; 39.6 ± 19.0 vs. 55.0 ± 19.0 dB, respectively). Severity improved in both groups; however, the between-group difference in change did not reach statistical significance (p = 0.077). Air-conduction PTA improved within the biologics group (p = 0.031); however, the between-group difference in PTA change was not significant (p = 0.249). Systemic corticosteroids were discontinued in the biologics group (0.00 ± 0.00 mg/day) but remained required in the non-biologics group (1.35 ± 1.55 mg/day; p = 0.011).Conclusion In this pilot real-world cohort, biologic therapy used for comorbid type 2 airway disease was associated with a reduced corticosteroid burden and lower post-index EOM severity. Air-conduction PTA improved within the biologics group; however, the between-group difference in PTA change was not statistically significant, and the hearing findings should therefore be considered exploratory. These preliminary findings should be interpreted cautiously and may help inform adequately powered future studies.
SN - 0301-1569
SN - 1423-0275
ER -